![Sean Cao](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sean Cao
Corporate Officer/Principal chez
NOVABRIDGE BIOSCIENCES
Fortune : 210 815 $ au 31/08/2026
Profil
Sean Wuxiong Cao was the founder of Everest Medicines Ltd., founded in 2017, where the title held was CEO from 2017 to 2020.
Dr. Cao is also the founder of Abio-X Holdings, Inc...
Current jobs include Managing Director at CBC Group (Singapore) Pte.
Ltd. since 2016, Director at NiKang Therapeutics, Inc., and Chief Business Development Officer at NovaBridge Biosciences starting in 2026.
Former jobs include Chief Executive Officer & Director at ENSEM Therapeutics, Inc., Director at Aureon Biosciences, Inc. from 2009 to 2010, Manager-Product Development at Johnson & Johnson in 2008, Associate at New Leaf Venture Partners LLC from 2008 to 2009, and Senior Research Investigator at Sanofi-Aventis U.S.
LLC from 2001 to 2004.
Education includes an MBA from the University of Pennsylvania, a doctorate from Nankai University, and a doctorate from the University of Virginia conferred in 1990.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 09/09/2026 | 266 467 ( 0,14% ) | 210 815 $ | 31/08/2026 |
Postes actifs de Sean Cao
| Sociétés | Poste | Début |
|---|---|---|
| NOVABRIDGE BIOSCIENCES | Corporate Officer/Principal | 03/09/2025 |
NiKang Therapeutics, Inc.
 NiKang Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule oncology medicines to help patients | Directeur/Membre du Conseil | - |
CBC Group (Singapore) Pte. Ltd.
 CBC Group (Singapore) Pte. Ltd. Investment ManagersFinance CBC Group invests in middle market companies located in China. The firm focuses on pharmaceutical, biotechnology, medical technology and healthcare service sectors. It provides financing in the form of equity, debt and non-dilutive financing for for buyout, growth, royalty acquisitions, structured transactions and hybrid financings. It acquires controlling stake in the company. | Directeur/Membre du Conseil | 01/10/2016 |
Abio-X Holdings, Inc. | Directeur Général | - |
Anciens postes connus de Sean Cao
| Sociétés | Poste | Fin |
|---|---|---|
ENSEM Therapeutics, Inc.
 ENSEM Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops molecule precision medicines for oncology | Directeur Général | 05/06/2023 |
| EVEREST MEDICINES LIMITED | Directeur Général | 01/02/2020 |
Aureon Biosciences, Inc.
 Aureon Biosciences, Inc. BiotechnologyHealth Technology Develops predictive tests for cancer recurrence and provides contract research services | Directeur/Membre du Conseil | 01/03/2010 |
New Leaf Venture Partners LLC
 New Leaf Venture Partners LLC Investment ManagersFinance New Leaf Ventures invests in public and private healthcare technology companies located in the US. The firm participates in early and later-stage capital requirements. | Analyste en capital-investissement | 01/09/2009 |
New Leaf Venture Partners LLC
New Leaf Venture Partners LLC Investment ManagersFinance New Leaf Ventures invests in public and private healthcare technology companies located in the US. The firm participates in early and later-stage capital requirements. | Analyste en capital-investissement | 31/08/2009 |
Formation de Sean Cao
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
73
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Johnson & Johnson
 Johnson & Johnson Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in health care products | Health Technology |
Aureon Biosciences, Inc.
Aureon Biosciences, Inc. BiotechnologyHealth Technology Develops predictive tests for cancer recurrence and provides contract research services | Health Technology |
University of Virginia
 University of Virginia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New Leaf Venture Partners LLC
New Leaf Venture Partners LLC Investment ManagersFinance New Leaf Ventures invests in public and private healthcare technology companies located in the US. The firm participates in early and later-stage capital requirements. | Finance |
Nankai University
 Nankai University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi-Aventis U.S. LLC
 Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Develops medicines, vaccines and provides specialized healthcare & clinical trail services | Health Technology |
CBC Group (Singapore) Pte. Ltd.
CBC Group (Singapore) Pte. Ltd. Investment ManagersFinance CBC Group invests in middle market companies located in China. The firm focuses on pharmaceutical, biotechnology, medical technology and healthcare service sectors. It provides financing in the form of equity, debt and non-dilutive financing for for buyout, growth, royalty acquisitions, structured transactions and hybrid financings. It acquires controlling stake in the company. | Finance |
Everest Medicines Ltd.
 Everest Medicines Ltd. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company which develops and commercializes therapies to address critical unmet medical needs | Health Technology |
I-Mab
 I-Mab Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for cancer and autoimmune diseases | Health Technology |
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule oncology medicines to help patients | Health Technology |
ENSEM Therapeutics, Inc.
ENSEM Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops molecule precision medicines for oncology | Health Technology |
Abio-X Holdings, Inc. |
